ELI LILLY & Co - FORM 10-K - EX-23 - CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM - February 19, 2020

Attached files

file filename
EX-10.4 - ELI LILLY AND COMPANY RELATIVE VALUE AWARD - ELI LILLY & Colly-20191231x10kexhibit104.htm
EX-32 - SECTION 1350 CERTIFICATION - ELI LILLY & Colly-20191231x10kexhibit32.htm
EX-31.2 - RULE 13A-14(A) CERTIFICATION OF JOSHUA L. SMILEY, SENIOR VICE PRESIDENT AND CFO - ELI LILLY & Colly-20191231x10kexhibit312.htm
EX-31.1 - RULE 13A-14(A) CERTIFICATION OF DAVID A. RICKS, CHAIRMAN, PRESIDENT, & CEO - ELI LILLY & Colly-20191231x10kexhibit311.htm
EX-21 - LIST OF SUBSIDIARIES AND AFFILIATES - ELI LILLY & Colly-20191231x10kexhibit21.htm
EX-10.5 - RESTRICTED STOCK UNIT AWARD TO AN EXECUTIVE OFFICER - ELI LILLY & Colly-20191231x10kexhibit105.htm
EX-10.3 - ELI LILLY AND COMPANY SHAREHOLDER VALUE AWARD (FOR EXECUTIVE OFFICERS) - ELI LILLY & Colly-20191231x10kexhibit103.htm
EX-10.2 - ELI LILLY AND COMPANY PERFORMANCE AWARD (FOR EXECUTIVE OFFICERS) - ELI LILLY & Colly-20191231x10kexhibit102.htm
EX-4.7 - DESCRIPTION OF THE COMPANY'S 0.625% EUR NOTES DUE 2031 AND 1.700% EUR NOTES DUE - ELI LILLY & Colly-20191231x10kexhibit47.htm
EX-4.6 - DESCRIPTION OF THE COMPANY'S 7 1/8% NOTES DUE 2025 - ELI LILLY & Colly-20191231x10kexhibit46.htm
EX-4.5 - DESCRIPTION OF THE COMPANY'S 6.77% NOTES DUE 2036 - ELI LILLY & Colly-20191231x10kexhibit45.htm
EX-4.4 - DESCRIPTION OF THE COMPANY'S 1.000% EUR NOTES DUE 2022, 1.625% EUR NOTES DUE 202 - ELI LILLY & Colly-20191231x10kexhibit44.htm
EX-4.3 - DESCRIPTION OF COMPANY'S COMMON STOCK - ELI LILLY & Colly-20191231x10kexhibit43.htm
10-K - 10-K - ELI LILLY & Colly-20191231x10xk.htm
Exhibit 23

Consent of Independent Registered Public Accounting Firm
We consent to the incorporation by reference in the Registration Statements (Form S-3 ASR No. 333-229735; and Form S-8 Nos. 333-104057 and 333-172422) of Eli Lilly and Company and in the related Prospectus of our reports dated February 19, 2020, with respect to the consolidated financial statements of Eli Lilly and Company and subsidiaries, and the effectiveness of internal control over financial reporting of Eli Lilly and Company and subsidiaries, included in this Annual Report (10-K) for the year ended December 31, 2019.


/s/ Ernst and Young LLP

Indianapolis, Indiana
February 19, 2020


ELI LILLY & Co Reports